Skip to main content
TipRanks
Go Ultimate75% OFF

Health & Life Co., Ltd. (1781) AI Stock Analysis

TW:1781

Health & Life Co., Ltd.

(TPEx:1781)

Select Model
Rating:37Underperform
Price Target:TWD 7.50â–¼(-1.32% Downside)
Action:reiterated
Date:11/20/26

The stock scores at the lowest possible level, reflecting a company in severe distress. The most significant factor is the deteriorating financial performance, marked by declining revenue, negative margins, and cash burn from operations. This is compounded by a bearish technical trend with the price below all key moving averages and weak momentum. The negative P/E ratio confirms a lack of earnings power. The company faces substantial fundamental and market-related risks.

Positive Factors
Lower LeverageThe sharp reduction in debt and conservative debt-to-equity position improve financial resilience and reduce interest-related pressure. This gives management more flexibility to sustain operations, fund recovery initiatives, and withstand continued earnings volatility over the next several quarters.
Negative Factors
Persistent LossesOngoing losses across net income, EBIT, and EBITDA indicate that current operations are not covering the economic cost of the business. Negative returns also reduce internal funding capacity and make a durable recovery dependent on restoring operating profitability.

Health & Life Co., Ltd. (1781) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%TW:1781-32.44%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 360.30M
Dividend Yield
―
Average Volume (3M)
45.22K
Price to Earnings (P/E)
-6.7
Beta (1Y)
0.42
Revenue Growth
-12.12%
EPS Growth
-17.27%
Country
TW
Employees
120
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Health & Life Co., Ltd. Business Overview & Revenue Model

Company Description

Health & Life Co., Ltd. is a global provider of medical devices. Established in 1996 and headquartered in New Taipei City, Taiwan, the company specializes in developing and distributing solutions for critical health sectors, including cardiovascular...

Health & Life Co., Ltd. Financial Statement Overview

Summary

Financial health is critically weak. Revenue is in persistent decline, gross margins have collapsed to 13.2%, and the company is generating substantial net losses (-13.8% margin). Operating cash flow has turned negative, indicating the core business is burning cash. The only mitigating factor is a low debt-to-equity ratio of 0.12, but this is overshadowed by rapidly eroding shareholder equity.

Income Statement

18Very Negative

Balance Sheet

55Neutral

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue388.27M398.05M706.39M601.17M797.54M811.88M
Gross Profit51.10M70.12M147.74M93.11M97.72M45.76M
EBITDA-34.66M-46.70M55.63M-7.84M11.85M-63.05M
Net Income-53.70M-61.67M24.24M-33.23M-17.55M-62.34M
Balance Sheet
Total Assets688.11M723.13M817.26M710.79M799.76M776.39M
Cash, Cash Equivalents and Short-Term Investments283.42M247.94M277.35M151.05M156.98M200.32M
Total Debt34.18M196.97M214.14M113.60M189.45M134.81M
Total Liabilities405.83M402.56M424.21M375.42M427.18M398.22M
Stockholders Equity282.28M320.57M393.05M335.37M372.58M378.18M
Cash Flow
Free Cash Flow-15.30M-5.01M30.14M76.82M-93.02M-145.04M
Operating Cash Flow-8.64M3.18M33.35M84.91M-80.69M-131.15M
Investing Cash Flow-6.80M41.96M-89.81M-8.78M-10.32M-16.02M
Financing Cash Flow26.85M-21.91M128.68M-74.67M25.91M-91.10M

Health & Life Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price7.60

Price Trends

50DMA9.56Negative
100DMA10.45Negative
200DMA11.13Negative

Market Momentum

MACD-0.50Positive
RSI23.67Positive
STOCH19.70Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:1781, the sentiment is Negative. The current price of 7.60 is below the 20-day moving average (MA) of 8.78, below the 50-day MA of 9.56, and below the 200-day MA of 11.13, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 23.67 is Positive, neither overbought nor oversold. The STOCH value of 19.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TW:1781.

Health & Life Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TW:1781 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TW:1781TW:178137UnderperformTWD 360.30M-6.72――-12.12%-17.27%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%20%TW:1781TW:4115TW:4117TW:4186TW:6549TW:6621Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:1781 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:1781Health & Life Co., Ltd.7.60-3.70-32.74%
TW:4115Sunder Biomedical Tech. Co., Ltd.6.80-1.85-21.39%
TW:4117General Biologicals Corp.7.00-5.05-41.91%
TW:4186Taiwan Advance Bio-Pharmaceutical, Inc.6.00-5.75-48.94%
TW:6549TaiwanJ Pharmaceuticals Co., Ltd.5.63-2.36-29.54%
TW:6621Unipharma Co., Ltd.10.95-1.25-10.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026